This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

reputable news agency


Ubrogepant beneficial for treating migraine during the prodrome

Ubrogepant beneficial for treating migraine during the prodrome

Ubrogepant is beneficial for the treatment of migraine when taken during the prodrome, according to a study published online Nov. 15 in The Lancet.

David W. Dodick, M.D., from the Mayo Clinic in Phoenix, and colleagues examined the efficacy, safety, and tolerability of ubrogepant 100 mg versus placebo for acute treatment of migraine when administered during the prodrome in a multicenter, randomized trial. Adults aged 18 to 75 years with at least a one-year history of migraine with or without aura and a history of two to eight per month with moderate-to-severe headache in the three months before screening were included.

Participants were randomly assigned to placebo to treat the first qualifying prodrome event and ubrogepant 100 mg to treat the second qualifying prodrome event or vice versa. The population included 480 participants and the modified intention-to-treat population included 477 participants.

The researchers found that within 24 hours after a dose, absence of moderate or severe headache occurred after 46 and 29 percent of 418 and 423 qualifying prodrome events that had been treated with ubrogepant and placebo, respectively (odds ratio, 2.09). Adverse events that occurred within 48 hours after study-drug administration were reported after 17 and 12 percent of qualifying prodrome events that had been treated with ubrogepant and , respectively.

"These results emphasize the clinical value of identifying the prodrome in people with migraine and highlight an important opportunity to intervene in the earliest phase of a attack to prevent progression to the headache phase, reduce disability, and improve outcomes," the authors write.

Several authors disclosed ties to biopharmaceutical companies, including AbbVie, which manufactures ubrogepant and funded the study.

More information: David W Dodick et al, Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA, The Lancet (2023). DOI: 10.1016/S0140-6736(23)01683-5

Journal information: The Lancet

Copyright © 2023 HealthDay. All rights reserved.

Citation: Ubrogepant beneficial for treating migraine during the prodrome (2023, November 22) retrieved 21 April 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Eptinezumab speeds pain, symptom relief from migraine attack


Feedback to editors